Ustekinumab  ||| S:0 E:12 ||| NNP
for  ||| S:12 E:16 ||| IN
the  ||| S:16 E:20 ||| DT
treatment  ||| S:20 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
moderate  ||| S:33 E:42 ||| JJ
to  ||| S:42 E:45 ||| TO
severe  ||| S:45 E:52 ||| JJ
psoriasis  ||| S:52 E:62 ||| NNS
This  ||| S:62 E:67 ||| DT
paper  ||| S:67 E:73 ||| NN
presents  ||| S:73 E:82 ||| VBZ
a  ||| S:82 E:84 ||| DT
summary  ||| S:84 E:92 ||| NN
of  ||| S:92 E:95 ||| IN
the  ||| S:95 E:99 ||| DT
evidence  ||| S:99 E:108 ||| NN
review  ||| S:108 E:115 ||| NN
group  ||| S:115 E:121 ||| NN
( ||| S:121 E:122 ||| -LRB-
ERG ||| S:122 E:125 ||| NNP
)  ||| S:125 E:127 ||| -RRB-
report  ||| S:127 E:134 ||| NN
into  ||| S:134 E:139 ||| IN
the  ||| S:139 E:143 ||| DT
clinical  ||| S:143 E:152 ||| JJ
effectiveness  ||| S:152 E:166 ||| NN
and  ||| S:166 E:170 ||| CC
cost-effectiveness  ||| S:170 E:189 ||| JJ
of  ||| S:189 E:192 ||| IN
ustekinumab  ||| S:192 E:204 ||| NN
for  ||| S:204 E:208 ||| IN
the  ||| S:208 E:212 ||| DT
treatment  ||| S:212 E:222 ||| NN
of  ||| S:222 E:225 ||| IN
moderate  ||| S:225 E:234 ||| JJ
to  ||| S:234 E:237 ||| TO
severe  ||| S:237 E:244 ||| JJ
psoriasis  ||| S:244 E:254 ||| NNS
based  ||| S:254 E:260 ||| VBN
upon  ||| S:260 E:265 ||| IN
a  ||| S:265 E:267 ||| DT
review  ||| S:267 E:274 ||| NN
of  ||| S:274 E:277 ||| IN
the  ||| S:277 E:281 ||| DT
manufacturer ||| S:281 E:293 ||| NN
's  ||| S:293 E:296 ||| POS
submission  ||| S:296 E:307 ||| NN
to  ||| S:307 E:310 ||| TO
the  ||| S:310 E:314 ||| DT
National  ||| S:314 E:323 ||| NNP
Institute  ||| S:323 E:333 ||| NNP
for  ||| S:333 E:337 ||| IN
Health  ||| S:337 E:344 ||| NNP
and  ||| S:344 E:348 ||| CC
Clinical  ||| S:348 E:357 ||| NNP
Excellence  ||| S:357 E:368 ||| NNP
( ||| S:368 E:369 ||| -LRB-
NICE ||| S:369 E:373 ||| NNP
)  ||| S:373 E:375 ||| -RRB-
as  ||| S:375 E:378 ||| IN
part  ||| S:378 E:383 ||| NN
of  ||| S:383 E:386 ||| IN
the  ||| S:386 E:390 ||| DT
single  ||| S:390 E:397 ||| JJ
technology  ||| S:397 E:408 ||| NN
appraisal  ||| S:408 E:418 ||| NN
( ||| S:418 E:419 ||| -LRB-
STA ||| S:419 E:422 ||| NNP
)  ||| S:422 E:424 ||| -RRB-
process ||| S:424 E:431 ||| NN
.  ||| S:431 E:433 ||| .
The  ||| S:433 E:437 ||| DT
submission ||| S:437 E:447 ||| NN
's  ||| S:447 E:450 ||| POS
main  ||| S:450 E:455 ||| JJ
evidence  ||| S:455 E:464 ||| NN
came  ||| S:464 E:469 ||| VBD
from  ||| S:469 E:474 ||| IN
three  ||| S:474 E:480 ||| CD
randomised  ||| S:480 E:491 ||| NNS
controlled  ||| S:491 E:502 ||| VBN
trials  ||| S:502 E:509 ||| NNS
( ||| S:509 E:510 ||| -LRB-
RCTs ||| S:510 E:514 ||| NNP
) ||| S:514 E:515 ||| -RRB-
,  ||| S:515 E:517 ||| ,
of  ||| S:517 E:520 ||| IN
reasonable  ||| S:520 E:531 ||| JJ
methodological  ||| S:531 E:546 ||| JJ
quality  ||| S:546 E:554 ||| NN
and  ||| S:554 E:558 ||| CC
measuring  ||| S:558 E:568 ||| VBG
a  ||| S:568 E:570 ||| DT
range  ||| S:570 E:576 ||| NN
of  ||| S:576 E:579 ||| IN
clinically  ||| S:579 E:590 ||| JJ
relevant  ||| S:590 E:599 ||| JJ
outcomes ||| S:599 E:607 ||| NNS
.  ||| S:607 E:609 ||| .
Higher  ||| S:609 E:616 ||| JJR
proportions  ||| S:616 E:628 ||| NNS
of  ||| S:628 E:631 ||| IN
participants  ||| S:631 E:644 ||| NNS
treated  ||| S:644 E:652 ||| VBN
with  ||| S:652 E:657 ||| IN
ustekinumab  ||| S:657 E:669 ||| NNS
( ||| S:669 E:670 ||| -LRB-
45  ||| S:670 E:673 ||| CD
mg  ||| S:673 E:676 ||| NNS
and  ||| S:676 E:680 ||| CC
90  ||| S:680 E:683 ||| CD
mg ||| S:683 E:685 ||| CD
)  ||| S:685 E:687 ||| -RRB-
than  ||| S:687 E:692 ||| IN
with  ||| S:692 E:697 ||| IN
placebo  ||| S:697 E:705 ||| NN
or  ||| S:705 E:708 ||| CC
etanercept  ||| S:708 E:719 ||| NNS
achieved  ||| S:719 E:728 ||| VBD
an  ||| S:728 E:731 ||| DT
improvement  ||| S:731 E:743 ||| NN
on  ||| S:743 E:746 ||| IN
the  ||| S:746 E:750 ||| DT
Psoriasis  ||| S:750 E:760 ||| NNP
Area  ||| S:760 E:765 ||| NNP
and  ||| S:765 E:769 ||| CC
Severity  ||| S:769 E:778 ||| NNP
Index  ||| S:778 E:784 ||| NNP
( ||| S:784 E:785 ||| -LRB-
PASI ||| S:785 E:789 ||| NNP
)  ||| S:789 E:791 ||| -RRB-
of  ||| S:791 E:794 ||| IN
at  ||| S:794 E:797 ||| IN
least  ||| S:797 E:803 ||| JJS
75 ||| S:803 E:805 ||| CD
%  ||| S:805 E:807 ||| NN
( ||| S:807 E:808 ||| -LRB-
PASI  ||| S:808 E:813 ||| NNP
75 ||| S:813 E:815 ||| CD
)  ||| S:815 E:817 ||| -RRB-
after  ||| S:817 E:823 ||| IN
12  ||| S:823 E:826 ||| CD
weeks ||| S:826 E:831 ||| NNS
.  ||| S:831 E:833 ||| .
There  ||| S:833 E:839 ||| EX
were  ||| S:839 E:844 ||| VBD
also  ||| S:844 E:849 ||| RB
statistically  ||| S:849 E:863 ||| RB
significant  ||| S:863 E:875 ||| JJ
differences  ||| S:875 E:887 ||| NNS
in  ||| S:887 E:890 ||| IN
favour  ||| S:890 E:897 ||| NN
of  ||| S:897 E:900 ||| IN
ustekinumab  ||| S:900 E:912 ||| NN
over  ||| S:912 E:917 ||| IN
placebo  ||| S:917 E:925 ||| NN
for  ||| S:925 E:929 ||| IN
PASI  ||| S:929 E:934 ||| NNP
50  ||| S:934 E:937 ||| CD
and  ||| S:937 E:941 ||| CC
PASI  ||| S:941 E:946 ||| NNP
90  ||| S:946 E:949 ||| CD
results ||| S:949 E:956 ||| NNS
,  ||| S:956 E:958 ||| ,
and  ||| S:958 E:962 ||| CC
for  ||| S:962 E:966 ||| IN
ustekinumab  ||| S:966 E:978 ||| NN
over  ||| S:978 E:983 ||| IN
etanercept  ||| S:983 E:994 ||| NN
for  ||| S:994 E:998 ||| IN
PASI  ||| S:998 E:1003 ||| NNP
90  ||| S:1003 E:1006 ||| CD
results ||| S:1006 E:1013 ||| NNS
.  ||| S:1013 E:1015 ||| .
A  ||| S:1015 E:1017 ||| DT
weight-based  ||| S:1017 E:1030 ||| JJ
subgroup  ||| S:1030 E:1039 ||| JJ
dosing  ||| S:1039 E:1046 ||| JJ
analysis  ||| S:1046 E:1055 ||| NN
for  ||| S:1055 E:1059 ||| IN
each  ||| S:1059 E:1064 ||| DT
trial  ||| S:1064 E:1070 ||| NN
was  ||| S:1070 E:1074 ||| VBD
presented ||| S:1074 E:1083 ||| VBN
,  ||| S:1083 E:1085 ||| ,
but  ||| S:1085 E:1089 ||| CC
the  ||| S:1089 E:1093 ||| DT
methodology  ||| S:1093 E:1105 ||| NN
was  ||| S:1105 E:1109 ||| VBD
poorly  ||| S:1109 E:1116 ||| RB
described  ||| S:1116 E:1126 ||| VBN
and  ||| S:1126 E:1130 ||| CC
no  ||| S:1130 E:1133 ||| DT
statistical  ||| S:1133 E:1145 ||| JJ
analysis  ||| S:1145 E:1154 ||| NN
to  ||| S:1154 E:1157 ||| TO
support  ||| S:1157 E:1165 ||| VB
the  ||| S:1165 E:1169 ||| DT
chosen  ||| S:1169 E:1176 ||| JJ
weight  ||| S:1176 E:1183 ||| NN
threshold  ||| S:1183 E:1193 ||| NN
was  ||| S:1193 E:1197 ||| VBD
presented ||| S:1197 E:1206 ||| VBN
.  ||| S:1206 E:1208 ||| .
The  ||| S:1208 E:1212 ||| DT
manufacturer  ||| S:1212 E:1225 ||| NN
carried  ||| S:1225 E:1233 ||| VBD
out  ||| S:1233 E:1237 ||| RP
a  ||| S:1237 E:1239 ||| DT
mixed  ||| S:1239 E:1245 ||| JJ
treatment  ||| S:1245 E:1255 ||| NN
comparison  ||| S:1255 E:1266 ||| NN
( ||| S:1266 E:1267 ||| -LRB-
MTC ||| S:1267 E:1270 ||| NNP
) ||| S:1270 E:1271 ||| -RRB-
;  ||| S:1271 E:1273 ||| :
however ||| S:1273 E:1280 ||| RB
,  ||| S:1280 E:1282 ||| ,
the  ||| S:1282 E:1286 ||| DT
appropriateness  ||| S:1286 E:1302 ||| NN
of  ||| S:1302 E:1305 ||| IN
some  ||| S:1305 E:1310 ||| DT
of  ||| S:1310 E:1313 ||| IN
the  ||| S:1313 E:1317 ||| DT
methodological  ||| S:1317 E:1332 ||| JJ
aspects  ||| S:1332 E:1340 ||| NNS
of  ||| S:1340 E:1343 ||| IN
the  ||| S:1343 E:1347 ||| DT
MTC  ||| S:1347 E:1351 ||| NNP
is  ||| S:1351 E:1354 ||| VBZ
uncertain ||| S:1354 E:1363 ||| JJ
.  ||| S:1363 E:1365 ||| .
The  ||| S:1365 E:1369 ||| DT
incidence  ||| S:1369 E:1379 ||| NN
of  ||| S:1379 E:1382 ||| IN
adverse  ||| S:1382 E:1390 ||| JJ
events  ||| S:1390 E:1397 ||| NNS
was  ||| S:1397 E:1401 ||| VBD
similar  ||| S:1401 E:1409 ||| JJ
between  ||| S:1409 E:1417 ||| IN
groups  ||| S:1417 E:1424 ||| NNS
at  ||| S:1424 E:1427 ||| IN
12  ||| S:1427 E:1430 ||| CD
weeks  ||| S:1430 E:1436 ||| NNS
and  ||| S:1436 E:1440 ||| CC
withdrawals  ||| S:1440 E:1452 ||| NNS
due  ||| S:1452 E:1456 ||| JJ
to  ||| S:1456 E:1459 ||| TO
adverse  ||| S:1459 E:1467 ||| JJ
events  ||| S:1467 E:1474 ||| NNS
were  ||| S:1474 E:1479 ||| VBD
low  ||| S:1479 E:1483 ||| JJ
and  ||| S:1483 E:1487 ||| CC
less  ||| S:1487 E:1492 ||| RBR
frequent  ||| S:1492 E:1501 ||| JJ
in  ||| S:1501 E:1504 ||| IN
the  ||| S:1504 E:1508 ||| DT
ustekinumab  ||| S:1508 E:1520 ||| NN
than  ||| S:1520 E:1525 ||| IN
in  ||| S:1525 E:1528 ||| IN
the  ||| S:1528 E:1532 ||| DT
placebo  ||| S:1532 E:1540 ||| NN
or  ||| S:1540 E:1543 ||| CC
etanercept  ||| S:1543 E:1554 ||| JJ
groups ||| S:1554 E:1560 ||| NNS
;  ||| S:1560 E:1562 ||| :
however ||| S:1562 E:1569 ||| RB
,  ||| S:1569 E:1571 ||| ,
statistical  ||| S:1571 E:1583 ||| JJ
comparisons  ||| S:1583 E:1595 ||| NNS
were  ||| S:1595 E:1600 ||| VBD
not  ||| S:1600 E:1604 ||| RB
reported ||| S:1604 E:1612 ||| VBD
.  ||| S:1612 E:1614 ||| .
The  ||| S:1614 E:1618 ||| DT
manufacturer ||| S:1618 E:1630 ||| NN
's  ||| S:1630 E:1633 ||| POS
economic  ||| S:1633 E:1642 ||| JJ
model  ||| S:1642 E:1648 ||| NN
of  ||| S:1648 E:1651 ||| IN
treatments  ||| S:1651 E:1662 ||| NNS
for  ||| S:1662 E:1666 ||| IN
psoriasis  ||| S:1666 E:1676 ||| VBG
compared  ||| S:1676 E:1685 ||| VBN
ustekinumab  ||| S:1685 E:1697 ||| VBN
with  ||| S:1697 E:1702 ||| IN
other  ||| S:1702 E:1708 ||| JJ
biological  ||| S:1708 E:1719 ||| JJ
therapies ||| S:1719 E:1728 ||| NNS
.  ||| S:1728 E:1730 ||| .
The  ||| S:1730 E:1734 ||| DT
model  ||| S:1734 E:1740 ||| NN
used  ||| S:1740 E:1745 ||| VBD
a  ||| S:1745 E:1747 ||| DT
reasonable  ||| S:1747 E:1758 ||| JJ
approach ||| S:1758 E:1766 ||| NN
;  ||| S:1766 E:1768 ||| :
however ||| S:1768 E:1775 ||| RB
,  ||| S:1775 E:1777 ||| ,
it  ||| S:1777 E:1780 ||| PRP
is  ||| S:1780 E:1783 ||| VBZ
not  ||| S:1783 E:1787 ||| RB
clear  ||| S:1787 E:1793 ||| JJ
whether  ||| S:1793 E:1801 ||| IN
the  ||| S:1801 E:1805 ||| DT
clinical  ||| S:1805 E:1814 ||| JJ
effectiveness  ||| S:1814 E:1828 ||| NN
estimates  ||| S:1828 E:1838 ||| NNS
from  ||| S:1838 E:1843 ||| IN
the  ||| S:1843 E:1847 ||| DT
subgroup  ||| S:1847 E:1856 ||| JJ
analysis ||| S:1856 E:1864 ||| NN
,  ||| S:1864 E:1866 ||| ,
used  ||| S:1866 E:1871 ||| VBN
in  ||| S:1871 E:1874 ||| IN
the  ||| S:1874 E:1878 ||| DT
base-case  ||| S:1878 E:1888 ||| JJ
analysis ||| S:1888 E:1896 ||| NN
,  ||| S:1896 E:1898 ||| ,
were  ||| S:1898 E:1903 ||| VBD
methodologically  ||| S:1903 E:1920 ||| JJ
appropriate ||| S:1920 E:1931 ||| JJ
.  ||| S:1931 E:1933 ||| .
The  ||| S:1933 E:1937 ||| DT
base-case  ||| S:1937 E:1947 ||| JJ
incremental  ||| S:1947 E:1959 ||| JJ
cost-effectiveness  ||| S:1959 E:1978 ||| JJ
ratio  ||| S:1978 E:1984 ||| NN
for  ||| S:1984 E:1988 ||| IN
ustekinumab  ||| S:1988 E:2000 ||| FW
versus  ||| S:2000 E:2007 ||| FW
supportive  ||| S:2007 E:2018 ||| JJ
care  ||| S:2018 E:2023 ||| NN
was  ||| S:2023 E:2027 ||| VBD
29,587  ||| S:2027 E:2034 ||| CD
pounds  ||| S:2034 E:2041 ||| NNS
per  ||| S:2041 E:2045 ||| IN
quality-adjusted  ||| S:2045 E:2062 ||| JJ
life-year  ||| S:2062 E:2072 ||| NN
( ||| S:2072 E:2073 ||| -LRB-
QALY ||| S:2073 E:2077 ||| NNP
) ||| S:2077 E:2078 ||| -RRB-
.  ||| S:2078 E:2080 ||| .
In  ||| S:2080 E:2083 ||| IN
one-way  ||| S:2083 E:2091 ||| JJ
sensitivity  ||| S:2091 E:2103 ||| NN
analysis  ||| S:2103 E:2112 ||| NN
the  ||| S:2112 E:2116 ||| DT
model  ||| S:2116 E:2122 ||| NN
was  ||| S:2122 E:2126 ||| VBD
most  ||| S:2126 E:2131 ||| RBS
sensitive  ||| S:2131 E:2141 ||| JJ
to  ||| S:2141 E:2144 ||| TO
the  ||| S:2144 E:2148 ||| DT
number  ||| S:2148 E:2155 ||| NN
of  ||| S:2155 E:2158 ||| IN
hospital  ||| S:2158 E:2167 ||| NN
days  ||| S:2167 E:2172 ||| NNS
associated  ||| S:2172 E:2183 ||| VBN
with  ||| S:2183 E:2188 ||| IN
supportive  ||| S:2188 E:2199 ||| JJ
care ||| S:2199 E:2203 ||| NN
,  ||| S:2203 E:2205 ||| ,
the  ||| S:2205 E:2209 ||| DT
cost  ||| S:2209 E:2214 ||| NN
estimate  ||| S:2214 E:2223 ||| NN
for  ||| S:2223 E:2227 ||| IN
intermittent  ||| S:2227 E:2240 ||| CD
etanercept  ||| S:2240 E:2251 ||| CD
25  ||| S:2251 E:2254 ||| CD
mg  ||| S:2254 E:2257 ||| NNS
and  ||| S:2257 E:2261 ||| CC
the  ||| S:2261 E:2265 ||| DT
utility  ||| S:2265 E:2273 ||| NN
scores  ||| S:2273 E:2280 ||| NNS
used ||| S:2280 E:2284 ||| VBN
.  ||| S:2284 E:2286 ||| .
In  ||| S:2286 E:2289 ||| IN
the  ||| S:2289 E:2293 ||| DT
ERG ||| S:2293 E:2296 ||| NNP
's  ||| S:2296 E:2299 ||| POS
scenario  ||| S:2299 E:2308 ||| NN
analysis  ||| S:2308 E:2317 ||| NN
the  ||| S:2317 E:2321 ||| DT
model  ||| S:2321 E:2327 ||| NN
was  ||| S:2327 E:2331 ||| VBD
most  ||| S:2331 E:2336 ||| RBS
sensitive  ||| S:2336 E:2346 ||| JJ
to  ||| S:2346 E:2349 ||| TO
the  ||| S:2349 E:2353 ||| DT
price  ||| S:2353 E:2359 ||| NN
of  ||| S:2359 E:2362 ||| IN
ustekinumab  ||| S:2362 E:2374 ||| CD
90  ||| S:2374 E:2377 ||| CD
mg ||| S:2377 E:2379 ||| NN
,  ||| S:2379 E:2381 ||| ,
the  ||| S:2381 E:2385 ||| DT
proportion  ||| S:2385 E:2396 ||| NN
of  ||| S:2396 E:2399 ||| IN
patients  ||| S:2399 E:2408 ||| NNS
with  ||| S:2408 E:2413 ||| IN
baseline  ||| S:2413 E:2422 ||| JJ
weight  ||| S:2422 E:2429 ||| NN
>  ||| S:2429 E:2431 ||| CD
100  ||| S:2431 E:2435 ||| CD
kg  ||| S:2435 E:2438 ||| NNS
and  ||| S:2438 E:2442 ||| CC
the  ||| S:2442 E:2446 ||| DT
relative  ||| S:2446 E:2455 ||| JJ
risk  ||| S:2455 E:2460 ||| NN
of  ||| S:2460 E:2463 ||| IN
intermittent  ||| S:2463 E:2476 ||| FW
versus  ||| S:2476 E:2483 ||| FW
continuous  ||| S:2483 E:2494 ||| FW
etanercept  ||| S:2494 E:2505 ||| JJ
25  ||| S:2505 E:2508 ||| CD
mg ||| S:2508 E:2510 ||| NNS
.  ||| S:2510 E:2512 ||| .
In  ||| S:2512 E:2515 ||| IN
the  ||| S:2515 E:2519 ||| DT
ERG ||| S:2519 E:2522 ||| NNP
's  ||| S:2522 E:2525 ||| POS
probabilistic  ||| S:2525 E:2539 ||| JJ
sensitivity  ||| S:2539 E:2551 ||| NN
analysis  ||| S:2551 E:2560 ||| NN
ustekinumab  ||| S:2560 E:2572 ||| NNS
had  ||| S:2572 E:2576 ||| VBD
the  ||| S:2576 E:2580 ||| DT
highest  ||| S:2580 E:2588 ||| JJS
probability  ||| S:2588 E:2600 ||| NN
of  ||| S:2600 E:2603 ||| IN
being  ||| S:2603 E:2609 ||| VBG
cost-effective  ||| S:2609 E:2624 ||| JJ
at  ||| S:2624 E:2627 ||| IN
conventional  ||| S:2627 E:2640 ||| JJ
NICE  ||| S:2640 E:2645 ||| NNP
thresholds ||| S:2645 E:2655 ||| NN
,  ||| S:2655 E:2657 ||| ,
assuming  ||| S:2657 E:2666 ||| VBG
the  ||| S:2666 E:2670 ||| DT
same  ||| S:2670 E:2675 ||| JJ
price  ||| S:2675 E:2681 ||| NN
for  ||| S:2681 E:2685 ||| IN
the  ||| S:2685 E:2689 ||| DT
45-mg  ||| S:2689 E:2695 ||| NNP
and  ||| S:2695 E:2699 ||| CC
90-mg  ||| S:2699 E:2705 ||| CD
doses ||| S:2705 E:2710 ||| NNS
;  ||| S:2710 E:2712 ||| :
however ||| S:2712 E:2719 ||| RB
,  ||| S:2719 E:2721 ||| ,
doubling  ||| S:2721 E:2730 ||| VBG
the  ||| S:2730 E:2734 ||| DT
price  ||| S:2734 E:2740 ||| NN
of  ||| S:2740 E:2743 ||| IN
ustekinumab  ||| S:2743 E:2755 ||| CD
90  ||| S:2755 E:2758 ||| CD
mg  ||| S:2758 E:2761 ||| NNS
resulted  ||| S:2761 E:2770 ||| VBD
in  ||| S:2770 E:2773 ||| IN
ustekinumab  ||| S:2773 E:2785 ||| VBG
no  ||| S:2785 E:2788 ||| DT
longer  ||| S:2788 E:2795 ||| RB
dominating  ||| S:2795 E:2806 ||| VBG
the  ||| S:2806 E:2810 ||| DT
comparators ||| S:2810 E:2821 ||| NN
.  ||| S:2821 E:2823 ||| .
In  ||| S:2823 E:2826 ||| IN
conclusion ||| S:2826 E:2836 ||| NN
,  ||| S:2836 E:2838 ||| ,
the  ||| S:2838 E:2842 ||| DT
clinical  ||| S:2842 E:2851 ||| JJ
effectiveness  ||| S:2851 E:2865 ||| NN
and  ||| S:2865 E:2869 ||| CC
cost-effectiveness  ||| S:2869 E:2888 ||| JJ
of  ||| S:2888 E:2891 ||| IN
ustekinumab  ||| S:2891 E:2903 ||| NN
in  ||| S:2903 E:2906 ||| IN
relation  ||| S:2906 E:2915 ||| NN
to  ||| S:2915 E:2918 ||| TO
other  ||| S:2918 E:2924 ||| JJ
drugs  ||| S:2924 E:2930 ||| NNS
in  ||| S:2930 E:2933 ||| IN
this  ||| S:2933 E:2938 ||| DT
class  ||| S:2938 E:2944 ||| NN
is  ||| S:2944 E:2947 ||| VBZ
uncertain ||| S:2947 E:2956 ||| JJ
.  ||| S:2956 E:2958 ||| .
Provisional  ||| S:2958 E:2970 ||| NNP
NICE  ||| S:2970 E:2975 ||| NNP
guidance  ||| S:2975 E:2984 ||| VBD
issued  ||| S:2984 E:2991 ||| VBN
as  ||| S:2991 E:2994 ||| IN
a  ||| S:2994 E:2996 ||| DT
result  ||| S:2996 E:3003 ||| NN
of  ||| S:3003 E:3006 ||| IN
the  ||| S:3006 E:3010 ||| DT
STA  ||| S:3010 E:3014 ||| NNP
states  ||| S:3014 E:3021 ||| NNS
that  ||| S:3021 E:3026 ||| IN
ustekinumab  ||| S:3026 E:3038 ||| NN
is  ||| S:3038 E:3041 ||| VBZ
recommended  ||| S:3041 E:3053 ||| VBN
as  ||| S:3053 E:3056 ||| IN
a  ||| S:3056 E:3058 ||| DT
treatment  ||| S:3058 E:3068 ||| NN
option  ||| S:3068 E:3075 ||| NN
for  ||| S:3075 E:3079 ||| IN
adults  ||| S:3079 E:3086 ||| NNS
with  ||| S:3086 E:3091 ||| IN
plaque  ||| S:3091 E:3098 ||| JJ
psoriasis  ||| S:3098 E:3108 ||| NN
when  ||| S:3108 E:3113 ||| WRB
a  ||| S:3113 E:3115 ||| DT
number  ||| S:3115 E:3122 ||| NN
of  ||| S:3122 E:3125 ||| IN
criteria  ||| S:3125 E:3134 ||| NNS
are  ||| S:3134 E:3138 ||| VBP
met ||| S:3138 E:3141 ||| VBN
.  ||| S:3141 E:3143 ||| .
Final  ||| S:3143 E:3149 ||| JJ
guidance  ||| S:3149 E:3158 ||| NN
is  ||| S:3158 E:3161 ||| VBZ
anticipated  ||| S:3161 E:3173 ||| VBN
in  ||| S:3173 E:3176 ||| IN
September  ||| S:3176 E:3186 ||| NNP
2009 ||| S:3186 E:3190 ||| CD
.  ||| S:3190 E:3192 ||| .
